Maslowska-Lipowicz I, Figlus M, Zuiderveld OP, Walczynski K. New 1-benzyl-4-hydroxypiperidine derivatives as non-imidazole histamine H3 receptor antagonists.
Arch Pharm (Weinheim) 2008;
341:762-73. [PMID:
19009544 DOI:
10.1002/ardp.200800070]
[Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
A series of 1-benzyl-4-(3-aminopropyloxy)piperidine and 1-benzyl-4-(5-aminopentyloxy)piperidine derivatives has been prepared. The 1-benzyl-4-hydroxypiperidine derivatives obtained were evaluated for their affinities at recombinant human histamine H(3 )receptor, stably expressed in HEK 293T cells. All compounds investigated show moderate to pronounced in-vitro affinities. The most potent antagonists in this series 9b2 (hH(3)R, pK(i) = 7.09), 9b1 (hH(3)R, pK(i) = 6.78), 9b5 (hH(3)R, pK(i) = 6.99), and 9b6 (hH(3)R, pK(i )= 6.97) were also tested in vitro as H(3 )receptor antagonists - the electrically evoked contraction of the guinea-pig jejunum. The histaminergic H(1) antagonism of selected compounds 9b1, 9b2, and 9b4-9b6 was established on the isolated guinea-pig ileum by conventional methods; the pA(2) values were compared with the potency of pyrilamine. The compounds did not show any H(1) antagonistic activity (pA(2) < 4; for pyrilamine pA(2) = 9.53).
Collapse